Back to Search Start Over

Utility of genetic testing in children with leukodystrophy.

Authors :
Zerem, Ayelet
Libzon, Stephanie
Ben Sira, Liat
Meirson, Hadas
Hausman-Kedem, Moran
Haviv, Noam
Yosovich, Keren
Mory, Adi
Baris Feldman, Hagit
Lev, Dorit
Lerman-Sagie, Tally
Fattal-Valevski, Aviva
Hacohen, Yael
Marom, Daphna
Source :
European Journal of Paediatric Neurology; Jul2023, Vol. 45, p29-35, 7p
Publication Year :
2023

Abstract

Leukodystrophies are monogenic disorders primarily affecting the white matter. We aimed to evaluate the utility of genetic testing and time-to-diagnosis in a retrospective cohort of children with suspected leukodystrophy. Medical records of patients who attended the leukodystrophy clinic at the Dana-Dwek Children's Hospital between June 2019 and December 2021 were retrieved. Clinical, molecular, and neuroimaging data were reviewed, and the diagnostic yield was compared across genetic tests. Sixty-seven patients (Female/Male ratio 35/32) were included. Median age at symptom onset was 9 months (interquartile range (IQR) 3–18 months), and median length of follow-up was 4.75 years (IQR 3–8.5). Time from symptom onset to a confirmed genetic diagnosis was 15months (IQR 11–30). Pathogenic variants were identified in 60/67 (89.6%) patients; classic leukodystrophy (55/67, 82.1%), leukodystrophy mimics (5/67, 7.5%). Seven patients (10.4%) remained undiagnosed. Exome sequencing showed the highest diagnostic yield (34/41, 82.9%), followed by single-gene sequencing (13/24, 54%), targeted panels (3/9, 33.3%) and chromosomal microarray (2/25, 8%). Familial pathogenic variant testing confirmed the diagnosis in 7/7 patients. A comparison between patients who presented before (n = 31) and after (n = 21) next-generation sequencing (NGS) became clinically available in Israel revealed that the time-to-diagnosis was shorter in the latter group with a median of 12months (IQR 3.5–18.5) vs. a median of 19 months (IQR 13–51) (p = 0.005). NGS carries the highest diagnostic yield in children with suspected leukodystrophy. Access to advanced sequencing technologies accelerates speed to diagnosis, which is increasingly crucial as targeted treatments become available. • NGS carries the highest diagnostic yield in leukodystrophy (LD). • CMA has low diagnostic yield in LD. • Access to next generation sequencing shortens time to diagnosis in LD patients. • LD frequencies differ between different geographical areas. [ABSTRACT FROM AUTHOR]

Details

Language :
English
ISSN :
10903798
Volume :
45
Database :
Supplemental Index
Journal :
European Journal of Paediatric Neurology
Publication Type :
Academic Journal
Accession number :
165042097
Full Text :
https://doi.org/10.1016/j.ejpn.2023.05.008